Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Similarity Between QL1209 and Perjeta in Healthy Male Participants
NCT07861139Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2026
- Primary completion
- Apr 2027
01
Overview
Phase 1, randomised, double-blind trial of QL1209 in breast cancer (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Area Under the Curve from Time Zero to Infinity at 99 days. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
QL1209
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07861139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07861139.